the present invention relates to novel solid pharmaceutical compositions obtained using a new production process , comprising a three - phase release system capable of reducing side effects and / or dependency from treatment , among some other benefits , when they are in the same composition and different from those obtained by the independent administration of pharmaceutically active agents . the administration of these novel solid pharmaceutical compositions , which have a three - phase release system , allow to have benefits such as increased efficiency of therapeutic effect and / or pharmaceutically active agents in lower concentrations and / or lower dose , and / or more extended times for administration and / or lower risk of some liver damage . such solid pharmaceutical compositions are composed of at least three layers to form an oral dosage unit , wherein at least each layer contains at least one pharmaceutically active agent belonging to group a ) corticosteroid and at least one agent belonging to group b ) non - steroidal anti - inflammatory drug , plus one or more pharmaceutically acceptable excipients . the pharmaceutically active agents , when administered orally in a single dosage form concomitantly cause a better therapeutic effect . the present invention is characterized by comprising a novel system of distribution of pharmaceutically active agents contained in an oral dosage unit with a three - phase release system . the release system is tree - phase because the oral dosage unit is comprised of at least three layers , wherein the first layer consists of a core located in the center of the oral dose unit ; the second underlayer covers at least half of the central core ; the third upper layer completely covers the central core and gives the final form of the oral dosage unit . according to the above , the pharmaceutically active agent of the corticosteroid group , and / or salts , and pharmaceutically acceptable excipients thereof are present in the first layer ; the pharmaceutically active agent of the non - steroidal anti - inflammatory group , and / or their salts and pharmaceutically acceptable excipients are present in the second and third layers . the three - phase release system of the solid dosage unit was determined from the behavior and / or pharmacokinetic characteristics of these pharmaceutically active agents when administered in an oral dosage ; also , the times for release of each pharmaceutically active agent are adjusted primarily to reduce side effects that they can cause and / or adverse reactions associated with the administration thereof , in order to obtain an effective , efficient and safe pharmaceutical composition with respect to those reported in the state of the art . these tablets that form the oral dosage unit may have a delayed release system , and / or an extended release system , and / or a modified release system , and / or an immediate - release system . the three - phase release system for pharmaceutically active agents of the dosage unit is useful for the treatment and / or control of body pain and / or inflammation of the same and / or related diseases . the three - phase release system contains the synergistic combination of such pharmaceutically active agents contained in at least one solid dosage unit for oral administration composed of at least three layers as follows : the first layer or core comprising at least a corticosteroid or pharmaceutically acceptable salts thereof with a delayed - release system , and / or an extended - release system , and at least one pharmaceutically acceptable excipient ; a second underlayer comprising at least one non - steroidal anti - inflammatory and / or pharmaceutically acceptable salts thereof with a modified - release system , and / or an immediate - release system , and at least one pharmaceutically acceptable excipient ; a third top layer comprising at least one non - steroidal anti - inflammatory , and / or pharmaceutically acceptable salts thereof with an extended - release system , and at least one pharmaceutically acceptable excipient . preferably , for the object of the present invention is used at least one core containing a corticosteroid agent and / or pharmaceutically acceptable salts thereof having a delayed release system ; at least one underlayer containing a non - steroidal anti - inflammatory agent and / or pharmaceutically acceptable salts thereof , having an immediate - release system and at least one top layer containing a non - steroidal anti - inflammatory agent and / or pharmaceutically acceptable salts thereof having an extended release system , in order to avoid antagonistic competition for cytochrome p - 450 in the liver , allowing to have the synergistic effect of the two pharmaceutically active agents . novel compositions product of this invention are characterized because the core comprises a ) at least one pharmaceutically active corticosteroid and / or its pharmaceutically acceptable salts , i ) at least one diluent and / or ii ) at least one binding agent , and / or iii ) at least one release polymer , and / or iv ) at least one lubricant and / or vii ) at least one solvent ; the underlayer comprises b ) at least one pharmaceutically active non - steroidal anti - inflammatory agent and / or its pharmaceutically acceptable salts or i ) at least one diluent , and / or ii ) at least one binding agent and / or iii *) at least one disintegrating agent , and / or iv ) at least one lubricant , and / or v ) at least one solvent ; the top layer comprises c ) at least one pharmaceutically active non - steroidal anti - inflammatory agent or its pharmaceutically acceptable salts and / or at least one diluent or at least one binding agent and / or at least one release polymer , and / or at least one lubricant , and / or at least one solvent . in addition , the layers forming the oral dosage unit may or may not contain other pharmaceutically acceptable excipients selected from : ph modifiers and / or alkalizing agents , among others . the pharmaceutically active corticosteroid a ) that is present in the core is present in a concentration ranging from 0 . 10 to 10 mg and is selected from the following group : hydrocortisone , cortisone , corticosterone , prednisone , prednisolone , 6α - methyl - prednisolone , tiamcinolone , betamethasone , dexamethasone , as well as their pharmaceutically acceptable salts and / or polymorphs and / or prodrugs and / or metabolites and / or amorphous and / or hemisolvates of each ; and / or combinations thereof . the pharmaceutically active group belonging to non - steroidal anti - inflammatory agent b ) that is present in the underlayer is present in a concentration ranging from 10 to 125 mg and is selected from the following group : aceclofenac , acetylsalicylic acid , ketoprofen , etodolac , flurbiprofen , piroxicam , indomethacin , ibuprofen , sulindac , naproxen , diclofenac , fenoprofen and their pharmaceutically acceptable salts , and / or polymorphs , and / or prodrugs , and / or metabolites , and / or amorphous , and / or hemisolvates of each of them ; and / or combinations thereof . the pharmaceutically active agent of the group belonging to non - steroid anti - inflammatory agents c ) that is present in the top layer is present in a concentration range that goes from 10 to 125 mg and is selected from the following group : aceclofenac , acetylsalicylic acid , ketoprofen , etodolac , flurbiprofen , piroxicam , indomethacin , ibuprofen , sulindac , naproxen , diclofenac , fenoprofen , and their pharmaceutically acceptable salts , and / or polymorphs , and / or prodrugs , and / or metabolites , and / or amorphous , and / or hemisolvates from each of them ; and / or combinations thereof . the diluent i ) for each layer is selected from : starch , and / or pre - gelatinized starch , and / or corn starch , and / or sugar , and / or sugar compressible , and / or isomalt , and / or microcrystalline cellulose , and / or lactose , and / or sorbitol , and / or sucrose , and / or tragacanth , and / or talc , and / or trehalose , and / or xylitol , and / or the combination of at least two of the above , among others . the binder agent ii ) for each layer is from : acacia , and / or agar , and / or alginic acid , and / or calcium carbonate , and / or calcium lactate , and / or carbomer , and / or carboxymethyl cellulose calcium , and / or microcrystalline cellulose , and / or cellulose , and / or ceratonia , and / or chitosan , and / or copovidone , and / or dextrates , and / or dextrin , and / or dextrose , and / or ethyl cellulose , and / or gelatin , and / or glyceryl behenate , and / or guar gum , and / or hydroxyethyl cellulose , and / or hydroxymethyl cellulose , and / or low - substituted hydroxypropyl cellulose , and / or hydroxypropyl starch , and / or methylcellulose , and / or inulin , and / or lactose monohydrate , and / or magnesium aluminum silicate , and / or maltodextrin , and / or methylcellulose , and / or polycarbophil , and / or polydextrose , and / or polyethylene oxide , and / or polymethacrylates , and / or polyvinylpyrrolidone , and / or iodine , and / or sodium alginate , and / or starch , and / or pre - gelatinized starch , and / or sucrose starch , and / or polyethylene glycol succinate , and / or zein , and / or the combination of at least two of the above , among others . the release polymer agent iii ) for the core and the top layer is selected from : acetiltributil citrate , and / or acetyl trietil citrate , and / or calcium carbonate , and / or carboxymethyl cellulose calcium and / or carboxymetyl cellulose sodium , and / or cellulose acetate , and / or cellulose , and / or ceresin , and / or cetyl alcohol , and / or chitosan , and / or diethyl phthalate , and / or dimethyl phthalate , and / or ethylcellulose , and / or gelatin , and / or liquid glucose , and / or glycerin , and / or glyceryl behenate , and / or glyceryl palmitostearate , and / or hydroxyethyl cellulose , and / or hydroxymethyl cellulose , and / or hydroxypropyl cellulose , and / or hypromellose , and / or hypromellose succinate , and / or hypromellose phthalate , and / or isomaltitol , and / or maltitol , and / or maltodextrin , and / or methylcellulose , and / or paraffin , and / or poloxamer , and / or polydextrose , and / or poly - ld - lactic acid , and / or polyethylene oxide , and / or polymethacrylates , and / or poli ( metil vinil ether / maleic anhydride ), and / or polyvinyl acetate phthalate , and / or shellac , and / or sodium chloride , and / or stearic acid , and / or sucrose , and / or talc , and / or titanium dioxide , and / or triacetin , and / or tributyl citrate , and / or triethyl citrate , and / or triolein , and / or carnauba wax , and / or microcrystalline wax , and / or white wax , and / or yellow wax , and / or xylitol , and / or zein , and / or carbomer and their derivatives , and / or the combination of at least two of the above , among others . the disintegrating agent iii *) for the underlayer is selected from the following group : alginic acid , and / or crospovidone , and / or ion exchange resins , and / or aluminum silicate , and / or magnesium silicate , and / or microcrystalline cellulose , and / or starch , and / or sodium glycolate starch , and / or modified cellulose gum , and / or pvp , and / or sodium dodecyl sulphate , and / or corn starch , and / or rice starch , and / or cross - linked n - vinyl - 2 - pyrrolidone , and / or croscarmellose sodium , and / or formaldehyde - casein , and / or a combination of at least two of the above , among others . the lubricant iv ) is selected from : calcium stearate , and / or glyceryl behenate , and / or glyceryl monostearate , and / or glyceryl palmitostearate , and / or lauric acid , and / or leucine , and / or magnesium stearate , and / or maltodextrin , and / or mineral oil , and / or light mineral oil , and / or myristic acid , and / or palmitic acid , and / or polyethylene glycol , and / or polyvinyl alcohol , and / or potassium benzoate , and / or sodium chloride , and / or sodium hyaluronate , and / or sodium lauryl sulfate , and / or sodium stearyl fumarate , and / or stearic acid , and / or talc , and / or hydrogenated vegetable oil , and / or zinc stearate , and / or a combination of at least two of the above , among others . the solvent agent v ) for each layer is selected from acetone , and / or methanol , and / or ethanol , and / or absolute ethanol , and / or 80 % ethanol , and / or 90 % ethanol , and / or chloroform , and / or benzyl alcohol , and / or benzyl benzoate , and / or butylene glycol , and / or castor oil , and / or corn oil , and / or cottonseed oil , and / or dibutyl phthalate , and / or diethyl phthalate , and / or dimethyl phthalate , and / or dimethyl sulfoxide , and / or dimethylacetamide , and / or ethyl acetate , and / or ethyl lactate , and / or ethyl oleate , and / or glycerine , and / or glycofurol , and / or isopropyl alcohol , and / or isopropyl myristate , and / or isopropyl palmitate , and / or chain triglycerides medium , and / or mineral oil , and / or light mineral oil , and / or octyldodecanol , and / or peanut oil , and / or polyethylene glycol , and / or propylene carbonate , and / or propylene , and / or pyrrolidone , and / or safflower , and / or sesame oil , and / or soybean oil , and / or sunflower oil , and / or triacetin , and / or tricaprylin , and / or triethyl citrate , and / or triolein , and / or water , and / or a combination of at least two of these , among others . the agent for ph modification is selected from : adipic acid , and / or boric acid , and / or calcium carbonate , and / or calcium lactate , and / or meglumine , and / or calcium phosphate , and / or citric acid monohydrate , and / or glycine , and / or maleic acid , and / or methionine , and / or monosodium glutamate , and / or potassium citrate , and / or sodium acetate , and / or sodium borate , and / or sodium carbonate , and / or sodium citrate dihydrate , and / or sodium hydroxide , and / or dibasic sodium phosphate , and / or monobasic sodium phosphate , and / or a combination of at least two of these , among others . the alkalizing agent is selected from the following group : potassium citrate , and / or sodium citrate , and / or sodium hydroxide , and / or potassium hydroxide , and / or sodium bicarbonate , and / or sodium carbonate , and / or calcium bicarbonate , and / or calcium carbonate , and / or potassium bicarbonate , and / or disodium phosphate , and / or trisodium phosphate , and / or arginine , and / or talc , and / or 1 - leucine , and / or the combination of at least two of these , among others . examples of novel pharmaceutical compositions containing the concomitant combination of a pharmaceutically active corticosteroid and a pharmaceutically active non - steroidal anti - inflammatory , as well as suitable excipients are also described ; which present a novel three - phase release system . however , the scope of the present invention is not limited to these examples : furthermore , such pharmaceutical compositions with three - phase release system are characterized by having a humidity of between 2 . 5 % and 5 % in powder ; a hardness of between 6 kg and 9 kg ; and friability less than 1 . process for preparing the solid oral dosage unit with three - phase release system : 1 . mix the pharmaceutically active corticosteroid , one or more diluents and one or more binders . 2 . granulate the above mixture with one or more solvents , sieve , dry , and sieve through a mesh . 1 . mix the pharmaceutically active non - steroidal anti - inflammatory , one or more diluents , and one or more binders . 2 . granulate the above mixture with one or more solvents , sieve , dry , and sieve through a mesh . 1 . mix the pharmaceutically active non - steroidal anti - inflammatory , one or more diluents , and one or more binders . 2 . granulate the above mixture with one or more solvents , sieve , dry , and sieve through a mesh . 1 . dose in each of the hoppers the core , the powder for the underlayer and the powder for the top layer . importantly , this pharmaceutical composition with a three - phase release system offers in a non - limitative way , advantages such as : an effective , efficient and safe concomitant pharmacological effect ; doses of the pharmaceutically active agents are low , which prevents secondary and / or side effects to the body by oral administration of both .
the present invention relates to pharmaceutical compositions including a triphasic release system , which may be delayed release and / or extended release and / or modified release and / or immediate release , of at least three layers for the formation of at least one dosage unit . each layer includes , as active pharmaceutical ingredients , at least one corticosteroid agent of the betamethasone type and / or the pharmaceutically acceptable salts thereof , at least one non - steroidal anti - inflammatory agent of the aceclofenac type and / or the pharmaceutically acceptable salts thereof , and at least one pharmaceutically acceptable excipient . also described is the novel production process . said triphasic release system generates an enhanced treatment effect to combat inflammation and body pain .